OWLSTONE MEDICAL LIMITED

1. OWLSTONE MEDICAL LIMITED 2016-03-04 → present
2. OWLSTONE LIMITED 2004-04-20 → 2016-03-04
3. TIGER DAWN LIMITED 2003-11-06 → 2004-04-20

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Grant Thornton UK LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Group expects that it will continue to incur losses as it seeks to develop its Breath Biopsy technology and prepare for future commercialisation, and will need to obtain further financing before the Group is sustainably cash generative. The Board has comprehensively reviewed the Group's funding requirements and it is the Directors' expectation, following the completion of the equity round in early 2025, that sufficient capital is present to continue in operational existence beyond the going concern assessment period. Following the completion of this latest close, it is the Directors' expectation that there is sufficient capital to continue in operational existence for the foreseeable future.”

Group structure

1. OWLSTONE MEDICAL LIMITED · parent
   1. Omed Health Limited 1% · United Kingdom · Dormant company
   2. Owlstone Medical Inc: 1% · USA · Support services for sales and R&D

Significant events

• “In January 2025, the Group completed the first close of its latest equity financing, raising net proceeds after expenses of £21.9 million, which included the maturity of the convertible loan note as per Note 19.”
• “In March 2025, the Group raised a further £1.1 million ($1.4 million) of net proceeds after expenses from the Cystic Fibrosis Foundation.”
• “In April 2025, the Group raised a further £1.2 million ($1.6 million) of net proceeds after expenses from existing shareholders.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

17

last 12 months

Capital events

16

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +53.4%

  £2,081,255 → £3,192,272

• Cash

  -92.6%

  £17,025,754 → £1,259,840

• Net assets

  -85.5%

  £21,352,361 → £3,105,757

• Employees

  +5.8%

  191 → 202

• Operating profit

  -11.4%

  -£20,911,125 → -£23,292,474

• Profit before tax

  -15%

  -£20,143,702 → -£23,160,723

• Wages

  +13.1%

  £10,619,905 → £12,009,261

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers